Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 828,724
  • Shares Outstanding, K 20,991
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,528 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.29
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.31 +22.19%
on 12/19/19
53.11 -25.66%
on 12/30/19
+6.21 (+18.67%)
since 12/17/19
3-Month
19.94 +97.99%
on 10/18/19
53.11 -25.66%
on 12/30/19
+19.00 (+92.77%)
since 10/17/19

Most Recent Stories

More News
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced...

JPM : 138.20 (+0.69%)
APRE : 39.48 (-7.02%)
Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS

The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.

AGIO : 52.86 (+2.54%)
GERN : 1.41 (-2.76%)
XLRN : 56.14 (-0.20%)
APRE : 39.48 (-7.02%)
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?

Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

JNJ : 149.17 (+0.65%)
XLRN : 56.14 (-0.20%)
GERN : 1.41 (-2.76%)
APRE : 39.48 (-7.02%)
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced...

JPM : 138.20 (+0.69%)
MS : 57.51 (+1.90%)
APRE : 39.48 (-7.02%)
Trade APRE with:

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

2nd Resistance Point 44.17
1st Resistance Point 41.83
Last Price 39.48
1st Support Level 38.08
2nd Support Level 36.68

See More

52-Week High 53.11
Last Price 39.48
Fibonacci 61.8% 38.59
Fibonacci 50% 34.10
Fibonacci 38.2% 29.62
52-Week Low 15.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar